Results 91 to 100 of about 35,110 (216)

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Heinemann, Volker, Hoff, Paulo M.
core   +1 more source

Development of cetuximab-resistant human nasopharyngeal carcinoma cell lines and mechanisms of drug resistance

Biomedicine & Pharmacotherapy, 2010
This work aimed to explore the induction of cetuximab-resistant human nasopharyngeal carcinoma (hNPC) 5-8F/Erbitux cells and the mechanisms of drug resistance. The 5-8F cells with high EGFR expression and cetuximab sensitivity were screened and then induced by stepwise exposure to increasing doses of cetuximab.
Qiang, Zuo, Min, Shi, Libo, Li, Jinzhang, Chen, Rongcheng, Luo   +4 more
openaire   +2 more sources

Coacervate‐Mediated Lysosome‐Targeting Antibody Delivery for Protein Degradation

Advanced Science, EarlyView.
Targeting coacervates to the lysosome in the cytoplasm is a challenge. Here, we convert a tetrapeptide into lysosome‐targeting, membrane‐translocating coacervates. The lysosome‐sorting peptide coacervates facilitate coacervate‐mediated delivery of antibody antigen complexes and a PROTAC compound to the lysosome for the targeted degradation of cancer ...
Dingdong Yuan, Yishu Bao, Zhiyi Xu, Zhong Zheng, Yongxu Han, Kai Cheng, Yuan‐Di Zhao, Jiang Xia   +7 more
wiley   +1 more source

Osteopontin Mediates Cetuximab Resistance via the MAPK Pathway in NSCLC Cells. [PDF]

Onco Targets Ther, 2019
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. The high expression of osteopontin (OPN) is an important factor that aggravates drug resistance and causes a poor prognosis in this disease. Therefore, understanding the molecular mechanism of OPN is critical for the treatment and prognosis of NSCLC.We used bioinformatics ...
Cui J, Wang J, Lin C, Liu J, Zuo W.
europepmc   +4 more sources

Generation of CCR4/CD7 Bispecific CAR‐T Cells Resistant to Fratricide and Exhaustion

Advanced Science, EarlyView.
The applications of CAR T‐cell therapy in T‐cell malignancies face limitations such as fratricide, effector‐cell exhaustion, and antigen‐escape. Herein, we developed fratricide‐ and exhaustion‐resistant CAR‐T cells that targeted CCR4 and CD7 simultaneously, with optional EGFRt safety switch. Additionally, scRNA‐seq unveiled new molecular targets, which
Sile Li, Yuanxin Li, Asif Rashid, Hong Kee Tan, Shing Chan, Man Yan Hui, Wilson Yau Ki Chan, Kee See Lam, Yinping Liu, Wenwei Tu, Wing Leung   +10 more
wiley   +1 more source

Immunoscintigraphy for therapy decision making and follow-up of biological therapies [PDF]

, 2016
With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets.
Auletta, S., Carideo, Luciano, Galli, Filippo, Lauri, Chiara, Pacilio, Massimiliano, Signore, Alberto, Valabrega, Stefano   +6 more
core   +2 more sources

Integrating Human Intestinal Organoids into FDA'S New Approach Methodologies for Drug Discovery

Advanced Science, EarlyView.
Illustration summarizes how human intestinal organoids (HIOs) are becoming transformative in preclinical research. Preclinical drug discovery pipelines often rely on animal models for ADMET studies, even though interspecies ADME gaps, poor external validity, and high attrition rates are common.
Debarun Patra, Ibrahim M. Sayed, Souhrid Mukherjee, Honit Piplani, Aida Habtezion, Michael J. Rosen, Jospeh C. Wu   +6 more
wiley   +1 more source

Revisiting Epidermal Growth Factor Receptor (EGFR) Amplification as a Target for Anti-EGFR Therapy: Analysis of Cell-Free Circulating Tumor DNA in Patients With Advanced Malignancies. [PDF]

, 2019
PurposeTo date, evidence for tissue epidermal growth factor receptor (EGFR) overexpression as a biomarker for anti-EGFR therapies has been weak. We investigated the genomic landscape of EGFR amplification in blood-derived cell-free tumor DNA (cfDNA ...
Fanta, Paul T, Goodman, Aaron, Kato, Shumei, Kurzrock, Razelle, Lanman, Richard B, Lee, Suzanna, Lippman, Scott M, Mareboina, Manvita, Okamura, Ryosuke, Patel, Sandip P, Raymond, Victoria M, Schwab, Richard B, Sicklick, Jason K, Vu, Peter   +13 more
core   +1 more source

A simplified genomic profiling approach predicts outcome in metastatic colorectal cancer [PDF]

, 2019
The response of metastatic colorectal cancer (mCRC) to the first-line conventional combination therapy is highly variable, reflecting the elevated heterogeneity of the disease.
Belardinilli, Francesca, Bellavia, Diana, Bonfiglio, Caterina, Canettieri, Gianluca, Capalbo, Carlo, Cardinali, Beatrice, Colella, Mariarosaria, Colicchia, Valeria, Coppa, Anna, Cortesi, Enrico, Filetti, Marco, Giannini, Giuseppe, Infante, Paola, Longo, Flavia, Magri, Valentina, Malapelle, Umberto, Marchetti, Paolo, Mezi, Silvia, Milanetti, Edoardo, Nicolussi, Arianna, Paci, Paola, Pecorari, Silvia, Petroni, Marialaura, Pisapia, Pasquale, Prete, Alessandra, Raimondo, Domenico, Santoni, Matteo, Tessitore, Alessandra, Troncone, Giancarlo, Valentini, Virginia   +29 more
core   +2 more sources

Boron Neutron Capture Therapy at a Crossroads: Translational Gap and Emerging Delivery Agents

Chemistry – A European Journal, EarlyView.
This review surveys recent advances in boron delivery agents for BNCT, emphasizing the shift from classical small molecules to multifunctional nanocarriers and theranostic systems. By integrating targeting, imaging, and therapy, next‐generation boron compounds aim to bridge the gap between (bio)chemical innovation and clinical translation.
Christoph Selg, Evamarie Hey‐Hawkins
wiley   +1 more source